AMEX · NNVC
Healthcare · Biotechnology
$1.04
Down-$0.02 (-1.92%)
Updated Sep 10, 2026, 11:51 PM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NNVC closed at $1.04 after 20 trading sessions, down 24.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $1.08 | $1.11 | $1.03 | $1.04 | 419.05K |
| Sep 8, 2026 | $1.11 | $1.13 | $1.08 | $1.08 | 265.05K |
| Sep 4, 2026 | $1.15 | $1.17 | $1.10 | $1.12 | 489.46K |
| Sep 3, 2026 | $1.15 | $1.1899 | $1.14 | $1.15 | 307.01K |
| Sep 2, 2026 | $1.24 | $1.28 | $1.16 | $1.17 | 502.95K |
| Sep 1, 2026 | $1.24 | $1.2506 | $1.21 | $1.21 | 204.02K |
| Aug 31, 2026 | $1.29 | $1.33 | $1.24 | $1.25 | 399.36K |
| Aug 28, 2026 | $1.26 | $1.2761 | $1.22 | $1.24 | 189.22K |
| Aug 27, 2026 | $1.27 | $1.29 | $1.26 | $1.28 | 239.49K |
| Aug 26, 2026 | $1.29 | $1.32 | $1.27 | $1.28 | 180.8K |
| Aug 25, 2026 | $1.28 | $1.33 | $1.28 | $1.29 | 237.78K |
| Aug 24, 2026 | $1.31 | $1.31 | $1.26 | $1.27 | 252.44K |
| Aug 21, 2026 | $1.33 | $1.39 | $1.31 | $1.33 | 250.26K |
| Aug 20, 2026 | $1.33 | $1.37 | $1.30 | $1.31 | 204.35K |
| Aug 19, 2026 | $1.35 | $1.39 | $1.34 | $1.34 | 332.7K |
| Aug 18, 2026 | $1.35 | $1.375 | $1.32 | $1.35 | 265.79K |
| Aug 17, 2026 | $1.35 | $1.41 | $1.35 | $1.36 | 335.25K |
| Aug 14, 2026 | $1.37 | $1.40 | $1.35 | $1.38 | 205.73K |
| Aug 13, 2026 | $1.38 | $1.3999 | $1.34 | $1.36 | 194.43K |
| Aug 12, 2026 | $1.41 | $1.43 | $1.345 | $1.37 | 241.74K |
The latest Smart Investors Daily articles mentioning NNVC.
NNVC research
Company profile and research snapshot.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 6, 2026 | Noble Capital Markets | Outperform | — |
| May 7, 2024 | EF Hutton | Buy | — |
| Feb 16, 2024 | EF Hutton | Buy | — |
| Apr 18, 2023 | EF Hutton | Buy | — |
| Feb 28, 2023 | EF Hutton | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 31, 2026
NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine
Benzinga · Aug 18, 2026
Under the leadership of Professor Katoto, NanoViricides, as the drug sponsor of NV-387 Oral Gummies, has received regulatory approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the
Benzinga · Aug 10, 2026
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received regulatory approval to begin a Phase II Clinical
Benzinga · Jul 28, 2026
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it is eagerly awaiting regulatory approval to begin a Phase II
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NNVC.
